You are here

  • Home
  • Archive
  • Volume 14, Issue 8
  • Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China

Article metrics

Article menu
Health economics
Original research
Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II–IIIA EGFR-mutated non-small cell lung cancer in China

 

Online download statistics by month:

Online download statistics by month: August 2024 to September 2025

AbstractFullPdf
Aug 202445445783
Sep 202437237163
Oct 202432231630
Nov 202428228327
Dec 202428928742
Jan 202525525430
Feb 2025413828
Mar 202513313193
Apr 2025434123
May 2025424133
Jun 2025242119
Jul 2025343323
Aug 2025413712
Sep 202510106
Total23422320512